Myriad Pushes For Isolated DNA Patents In Fed. Circ.

Law360, New York (April 4, 2011, 6:05 PM EDT) -- Myriad Genetics Inc. tried to persuade the Federal Circuit on Monday that seven of its patents for isolated human genes were not invalid for merely being products of nature, as a lower court ruled.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit heard the Association for Molecular Pathology argue, in response, that the seven isolated gene patents at issue were not materially different from their original form in the human body.

Judge Robert W. Sweet's March ruling in the U.S. District...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.